Continuation Rate of Atypical Antipsychotics After Discharge When Initiated in the Intensive Care Unit

Author:

Farrokh Salia12,Castle Amber C.1,Heavner Mojdeh1,Pisani Margaret A.13

Affiliation:

1. Yale New Haven Hospital, New Haven, CT, USA

2. Department of Pharmacy Practice and Administration, Critical Care Clinical Faculty, University of Saint Joseph School of Pharmacy, Hartford, CT, USA

3. Yale University School of Medicine, New Haven, CT, USA

Abstract

Purpose: The frequency with which atypical antipsychotics initiated in the intensive care unit (ICU) is unknown. While there is lack of evidence to support the exact duration of treatment, antipsychotics should not be continued chronically for agitation and psychosis related to critical illness. The objective of this study was to determine whether atypical antipsychotics initiated in the ICU at a large tertiary academic medical center were continued after hospital discharge. Safety outcomes were also assessed. Materials: A total of 1023 patients who received atypical antipsychotics during ICU stay were identified. Patients were assessed in a pseudo-randomized fashion until a sample of 191 patients was reached. After review of the exclusion criteria, the final study population was 100 patients. When antipsychotics were discontinued, progress notes were reviewed to identify the reason for discontinuation. Safety outcomes were assessed based on physician documentation in the medical charts. Results: Atypical antipsychotics were continued in 23% of patients. Atypical antipsychotics were discontinued in 1 patient due to QTc prolongation. Conclusions: Atypical antipsychotics initiated in the ICU are frequently continued after hospital discharge. Given the known risks associated with extended therapy, initiatives are needed to prevent inappropriate continuation.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Reference30 articles.

1. Abilify® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012.

2. Zyprexa® [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.

3. Seroquel® [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011.

4. Risperdal® [package insert]. Titusville, NJ: Janssen, LP; 2011.

5. Geodon® [package insert]. New York, NY: Pfizer Inc; 2009.

Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Central nervous system medication use around hospitalization;Journal of the American Geriatrics Society;2024-04-10

2. Antipsychotic Use for ICU Delirium and Associated Inflammatory Markers;Journal of Intensive Care Medicine;2023-09-19

3. Impact of a computer‐assisted pharmacy transitions of care process on medication de‐prescribing when transferring from the intensive care unit;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2023-07-31

4. Medication-related problems in critical care survivors: a systematic review;European Journal of Hospital Pharmacy;2023-05-04

5. Levetiracetam‐associated behavioral adverse events in neurocritical care patients;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-01-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3